Multiple sclerosis: Classification revisited reveals homogeneity and recapitulation

Annals of Neurology

Volumn 63, Issue 1, 2008, Pages 1-3

  Raine, Cedric S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEATH RECEPTOR; FC RECEPTOR; FIBRINOGEN; HEAT SHOCK PROTEIN 60; HLA D ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN G; MYELIN;

APOPTOSIS; DISEASE CLASSIFICATION; EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; MACROPHAGE; MORPHOMETRICS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION;

AUTOANTIGENS; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNOGLOBULIN G; MACROPHAGES; MULTIPLE SCLEROSIS; MYELIN PROTEINS; NERVE FIBERS, MYELINATED; OLIGODENDROGLIA;

EID: 39049134457     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21314     Document Type: Editorial

References (20)

1. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol.
2. Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006;354:942-955.
3. Lucchinetti CF, Brück W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity of pathogenesis. Brain 1996;6:259-274.
4. Lucchinetti CF, Brueck W, Rodriguez M, et al. Multiple sclerosis: lessons from neuropathology. Semin Neurol 1998;18:337-349.
5. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult Scler 1998;4:93-98.
6. Lucchinetti C, Brück W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 1999;122:2279-2295.
7. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
8. Lassmann H, Brück H, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-121.
9. Lassmann H, Ransohoff RM. The CD4-TM model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004;25:132-137.
10. Lassmann H. Recent neuropathological findings in MS - implications for diagnosis and therapy. J Neurol 2004;251:IV/2-IV/5.
11. Lassmann H, Brück W, Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210-218.
12. Stadelmann C, Ludwin S, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005;128:979-987.
13. Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages in myelin breakdown. Ann Neurol 1981;20:149-158.
14. Genain CP, Cannella B, Hauser S, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175.
15. Lee SC, Moore GRW, Golenwsky G, et al. A role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J Neuropathol Exp Neurol 1990;49:122-136.
16. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-468.
17. Raine CS, Scheinberg L, Waltz JM. Multiple sclerosis: oligodendrocyte survival and proliferation in an active, established lesion. Lab Invest 1981;45:534-546.
18. Bonetti B, Raine CS. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997;42:74-84.
19. Cannella B, Gaupp S, Omari KM, et al. Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions. J Neuroimmunol 2007;188:128-137.
20. Raine CS, Wu E, Ivanyi J, et al. Multiple sclerosis: a protective or pathogenic role for heat shock protein 60 in the central nervous system? Lab Invest 1996;75:109-122.